Black Diamond Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-T. Rowe Price Investment Management, Inc.(19.0%)
Black Diamond Therapeutics | SC 13G:超過5%持股股東披露文件-Vestal Point Capital, LP(8.9%),Ryan Wilder(8.9%)
Black Diamond Therapeutics | SC 13G:超過5%持股股東披露文件-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | 10-Q:2024財年三季報
Black Diamond Therapeutics | 8-K:黑鑽療法公佈2024年第三季度財務業績並提供公司最新情況
Black Diamond Therapeutics | SC 13G:超過5%持股股東披露文件-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | 8-K:重大事件
Black Diamond Therapeutics | 8-K:重大事件
Black Diamond Therapeutics | 4:持股變動聲明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股變動聲明-董事 Campbell Shannon
Black Diamond Therapeutics | 4:持股變動聲明-董事 Raman Prakash
Black Diamond Therapeutics | 4:持股變動聲明-股東 Versant Venture Capital VI, L.P.
Black Diamond Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Versant Ventures VI GP, L.P.(7.7%),Versant Ventures VI GP-GP, LLC(7.7%)等
Black Diamond Therapeutics | 10-Q:2024財年二季報
Black Diamond Therapeutics | 8-K:Black Diamond Therapeutics公佈2024年第二季度財務業績並提供公司最新情況
Black Diamond Therapeutics | 144:擬議出售證券
Black Diamond Therapeutics | 144:擬議出售證券
Black Diamond Therapeutics | 144:擬議出售證券
Black Diamond Therapeutics | 144:擬議出售證券
Black Diamond Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-T. Rowe Price Investment Management, Inc.(18.9%)
暫無數據
暫無數據